Literature DB >> 20433991

Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines.

Gary H Lyman1, Nicole M Kuderer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20433991     DOI： 10.1016/S0049-3848(10)70029-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  12 in total

1.  Thromboprophylaxis in multiple myeloma: is the evidence there?

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren
Journal:  Expert Rev Anticancer Ther       Date:  2012-03       Impact factor: 4.512

2.  Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer.

Authors:  Xiaoguang Yang; Helin Zhang; Fanyi Kong; Guochen Wang; Qianyu Gu; Zheng Zhao; Tiezhi Li; Mingming Ren; Zuosheng Li; Yang Guo
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 3.  The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis.

Authors:  Kate Burbury; Michael P MacManus
Journal:  Clin Exp Metastasis       Date:  2018-02-28       Impact factor: 5.150

4.  Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study.

Authors:  Cheng E Chee; Aneel A Ashrani; Randolph S Marks; Tanya M Petterson; Kent R Bailey; L Joseph Melton; John A Heit
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

Review 5.  Biomolecular markers of cancer-associated thromboembolism.

Authors:  Diana L Hanna; Richard H White; Ted Wun
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-21       Impact factor: 6.312

6.  Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study.

Authors:  Tan-Wei Chew; Churn-Shiouh Gau; Yu-Wen Wen; Li-Jiuan Shen; C Daniel Mullins; Fei-Yuan Hsiao
Journal:  BMC Cancer       Date:  2015-04-17       Impact factor: 4.430

7.  Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.

Authors:  Stefan Fruehauf; Burkhard Otremba; Oliver Stötzer; Christine Rudolph
Journal:  Adv Ther       Date:  2016-10-14       Impact factor: 3.845

8.  [Experts Consensus on Huisheng Oral Solution for Lung Cancer 
Anticoagulation Treatment at Perioperation Period (2016 version)].

Authors:  Qinghua Zhou; Junfeng Liu; Xiaoguang Yang; Helin Zhang; Fanyi Kong; Guochen Wang; Xianli Meng; Zhiquan Chen; Lijun Liu; Lu Li; Xiongzhi Wu; Yang Guo
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-11-20

9.  Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.

Authors:  Anna Falanga; Alfonso Vignoli; Erika Diani; Marina Marchetti
Journal:  Patient Relat Outcome Meas       Date:  2011-11-23

10.  Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.

Authors:  Sophie Nahon; Mansour Rastkhah; Meher Ben Abdelghani; Ravaka-Fatoma Soumoudronga; Isabelle Gasnereau; Jean-Luc Labourey
Journal:  Support Care Cancer       Date:  2015-10-27       Impact factor: 3.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.